Searchable abstracts of presentations at key conferences in endocrinology

ea0029p811 | Endocrine tumours and neoplasia | ICEECE2012

Parathyroid atypical adenomas: mutational screening of CDC73/HRPT2 gene

Pardi E. , Borsari S. , Banti C. , Saponaro F. , Torregrossa L. , Marcocci C. , Cetani F.

Atypical parathyroid adenomas represent a subset of tumors with histological features worrisome for carcinoma (PC), such as trabecular growth, fibrous bands and increased mitotic activity without unequivocal criteria of malignancy (local recurrence and/or metastasis). The question of whether these lesions might represent an anticipation of an aggressive clinical behavior that overtime may acquire the full blown features of malignancy remains to be established.<p class="abs...

ea0029p851 | Endocrine tumours and neoplasia | ICEECE2012

Can proteomic approach help us in diagnosis of Riedel’s thyroiditis? A case report

Donatini G. , Iacconi P. , Giusti L. , Da Valle Y. , Ciregia F. , Giannaccini G. , Torregrossa L. , Proietti A. , Mazzeo S. , Basolo F. , Lucacchini A.

Background: Riedel’s thyroiditis (RT) is a rare thyroid disease. Clinical and citological differential diagnosis with thyroid malignancy is difficult pre-operatively and often only pathological report may confirm the diagnosis.Methods: We report a case of a 72-year-old Italian woman with a known history of goiter, which showed a rapid increase in size at ultrasound check, suggesting malignancy. Based on non-diagnostic cytology (Thy 1), a total thyro...

ea0029p1758 | Thyroid cancer | ICEECE2012

BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated thyroid cancer patients: a 5 year follow up study

Viola D , Torregrossa L , Giannini R , Ugolini C , Biagini A , Romei C , Molinaro E , Agate L , Basolo F , Pinchera A , Vitti P , Elisei R

BRAFV600E mutation is the most frequent genetic alteration (29–83%) of papillary thyroid carcinoma (PTC). Many authors have demonstrated that the presence of the mutation is associated with a more advanced tumor stage at diagnosis and a worse outcome but anyone assessed if BRAFV600E mutation could be useful prognostic marker in low risk PTC patients (T1-T2N0M0, 7th TNM classification).Aim of this study was to evaluate if the presence of BRAFV600E mu...